Progressive myoclonus epilepsy in Gaucher Disease due to a new Gly–Gly mutation causing loss of an Exonic Splicing Enhancer
暂无分享,去创建一个
[1] M. Horowitz,et al. New Directions in Gaucher Disease , 2016, Human mutation.
[2] R. Guerrini,et al. Double-target Antisense U1snRNAs Correct Mis-splicing Due to c.639+861C>T and c.639+919G>A GLA Deep Intronic Mutations , 2016, Molecular Therapy: Nucleic Acids.
[3] J. Swensen,et al. The Splicing Efficiency of Activating HRAS Mutations Can Determine Costello Syndrome Phenotype and Frequency in Cancer , 2016, PLoS genetics.
[4] S. Mooney,et al. Clinical relevance of short-chain acyl-CoA dehydrogenase (SCAD) deficiency: Exploring the role of new variants including the first SCAD-disease-causing allele carrying a synonymous mutation , 2016, BBA clinical.
[5] R. Guerrini,et al. When silence is noise: infantile‐onset Barth syndrome caused by a synonymous substitution affecting TAZ gene transcription , 2016, Clinical genetics.
[6] Chava Kimchi-Sarfaty,et al. Exposing synonymous mutations. , 2014, Trends in genetics : TIG.
[7] C. Rosano,et al. Functional analysis of 11 novel GBA alleles , 2013, European Journal of Human Genetics.
[8] T. Berkelman,et al. A Defined Methodology for Reliable Quantification of Western Blot Data , 2013, Molecular Biotechnology.
[9] Ellen Sidransky,et al. The link between the GBA gene and parkinsonism , 2012, The Lancet Neurology.
[10] C. Kimchi-Sarfaty,et al. Understanding the contribution of synonymous mutations to human disease , 2011, Nature Reviews Genetics.
[11] E. Dardiotis,et al. β-Glucocerebrosidase gene mutations in two cohorts of Greek patients with sporadic Parkinson's disease. , 2011, Molecular genetics and metabolism.
[12] M. Horowitz,et al. The enigma of the E326K mutation in acid β-glucocerebrosidase. , 2011, Molecular genetics and metabolism.
[13] L. Bour,et al. A monozygotic twin pair with highly discordant Gaucher phenotypes. , 2011, Blood cells, molecules & diseases.
[14] E. Sidransky,et al. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA) , 2008, Human mutation.
[15] M. Horowitz,et al. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. , 2007, Human molecular genetics.
[16] K. Hodaňová,et al. Genetic and clinical features of patients with Gaucher disease in Hungary. , 2007, Blood cells, molecules & diseases.
[17] E. Sobreira,et al. Detection of 12 new mutations in Gaucher disease Brazilian patients. , 2006, Blood cells, molecules & diseases.
[18] B. Bembi,et al. Characterization of two novel GBA mutations causing Gaucher disease that lead to aberrant RNA species by using functional splicing assays , 2006, Human mutation.
[19] M. Horowitz,et al. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity , 2005 .
[20] S. Grossi,et al. Early Visual Seizures and Progressive Myoclonus Epilepsy in Neuronopathic Gaucher Disease Due to a Rare Compound Heterozygosity (N188S/S107L) , 2004, Epilepsia.
[21] D. Grinberg,et al. Functional analysis of 13 GBA mutant alleles identified in Gaucher disease patients: Pathogenic changes and “modifier” polymorphisms , 2004, Human mutation.
[22] J. D. den Dunnen,et al. Standardizing mutation nomenclature: Why bother? , 2003, Human mutation.
[23] R. Schiffmann,et al. Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3. , 2003, The Journal of pediatrics.
[24] J. Sussman,et al. X‐ray structure of human acid‐β‐glucosidase, the defective enzyme in Gaucher disease , 2003, EMBO reports.
[25] Ellen Sidransky,et al. Reciprocal and nonreciprocal recombination at the glucocerebrosidase gene region: implications for complexity in Gaucher disease. , 2003, American journal of human genetics.
[26] R. Schiffmann,et al. Myoclonic Epilepsy in Gaucher Disease: Genotype-Phenotype Insights from a Rare Patient Subgroup , 2003, Pediatric Research.
[27] A. Krainer,et al. Listening to silence and understanding nonsense: exonic mutations that affect splicing , 2002, Nature Reviews Genetics.
[28] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[29] J. K. Park,et al. Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. , 2000, American journal of human genetics.
[30] S. Antonarakis,et al. Mutation nomenclature extensions and suggestions to describe complex mutations: A discussion , 2000 .
[31] J. Sobrino,et al. Unusual expression of Gaucher's disease: cardiovascular calcifications in three sibs homozygous for the D409H mutation. , 1995, Journal of medical genetics.
[32] E. Beutler,et al. Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[33] E. Ginns,et al. Isolation of cDNA clones for human β-glucocerebrosidase using the λgtll expression system , 1984 .
[34] R. Glew,et al. beta-Glucosidase assays in the diagnosis of Gaucher's disease. , 1982, Clinical chemistry.
[35] S. Raghavan,et al. Leukocyte beta-glucosidase in homozygotes and heterozygotes for Gaucher disease. , 1980, American journal of human genetics.
[36] N. Higurashi,et al. Gaucher disease patient with myoclonus epilepsy and a novel mutation. , 2010, Pediatric neurology.
[37] Jong-Won Kim,et al. Gaucher disease: Identification of three new mutations in the Korean and Chinese (Taiwanese) populations , 1996, Human mutation.
[38] O. Reiner,et al. The human glucocerebrosidase gene and pseudogene: structure and evolution. , 1989, Genomics.
[39] R. Van Tiggelen,et al. Gaucher disease , 2019, Haematology.
[40] E. Ginns,et al. Isolation of cDNA clones for human beta-glucocerebrosidase using the lambda gt11 expression system. , 1984, Biochemical and biophysical research communications.